BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 16781756)

  • 1. The G490E mutation in reverse transcriptase does not impact tRNA primer selection by HIV-1 with altered PBS and A-loop.
    Xu W; Morrow CD
    Virology; 2006 Sep; 352(2):380-9. PubMed ID: 16781756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in both the U5 region and the primer-binding site influence the selection of the tRNA used for the initiation of HIV-1 reverse transcription.
    Kang SM; Wakefield JK; Morrow CD
    Virology; 1996 Aug; 222(2):401-14. PubMed ID: 8806524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleotide sequences within the U5 region of the viral RNA genome are the major determinants for an human immunodeficiency virus type 1 to maintain a primer binding site complementary to tRNA(His).
    Zhang Z; Kang SM; LeBlanc A; Hajduk SL; Morrow CD
    Virology; 1996 Dec; 226(2):306-17. PubMed ID: 8955050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine leukemia virus with a primer-binding site complementary to tRNALys,3 adapts to select new tRNAs for replication following extended in vitro culture.
    Palmer MT; McPherson S; Morrow CD
    Virology; 2005 Mar; 333(2):337-48. PubMed ID: 15721366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.
    Han W; Wind-Rotolo M; Kirkman RL; Morrow CD
    Virology; 2004 Dec; 330(1):221-32. PubMed ID: 15527848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the interaction between tRNA and primer binding site from characterization of a unique HIV-1 virus which stably maintains dual PBS complementary to tRNA(Gly) and tRNA(His).
    Li Y; Zhang Z; Kang SM; Buescher JL; Morrow CD
    Virology; 1997 Nov; 238(2):273-82. PubMed ID: 9400600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV type 1 that select tRNA(His) or tRNA(Lys1,2) as primers for reverse transcription exhibit different infectivities in peripheral blood mononuclear cells.
    Moore KL; Kosloff BR; Kelly NJ; Kirkman RL; Dupuy LC; McPherson S; Morrow CD
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):373-81. PubMed ID: 15157356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementarity between 3' terminal nucleotides of tRNA and primer binding site is a major determinant for selection of the tRNA primer used for initiation of HIV-1 reverse transcription.
    Yu Q; Morrow CD
    Virology; 1999 Feb; 254(1):160-8. PubMed ID: 9927583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of forced selection of tRNAs on HIV-1 replication and genome stability highlight preferences for selection of certain tRNAs.
    Ni N; Morrow CD
    Virus Res; 2007 Mar; 124(1-2):29-37. PubMed ID: 17070952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations within the primer binding site of the human immunodeficiency virus type 1 define sequence requirements essential for reverse transcription.
    Wakefield JK; Morrow CD
    Virology; 1996 Jun; 220(2):290-8. PubMed ID: 8661380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of A-loop complementarity with tRNAHis anticodon for continued selection of tRNAHis as the HIV reverse transcription primer.
    Ni N; Xu W; Morrow CD
    Virol J; 2007 Jan; 4():4. PubMed ID: 17214904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferences for the selection of unique tRNA primers revealed from analysis of HIV-1 replication in peripheral blood mononuclear cells.
    Moore-Rigdon KL; Kosloff BR; Kirkman RL; Morrow CD
    Retrovirology; 2005 Mar; 2():21. PubMed ID: 15790410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of murine leukemia virus replication complemented by yeast tRNA(Phe) reveals inherent preferences for the tRNA primer selected for reverse transcription.
    Palmer MT; Morrow CD
    Virology; 2004 Jul; 324(2):430-8. PubMed ID: 15207628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription.
    Lee R; Kaushik N; Modak MJ; Vinayak R; Pandey VN
    Biochemistry; 1998 Jan; 37(3):900-10. PubMed ID: 9454580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forced selection of tRNA(Glu) reveals the importance of two adenosine-rich RNA loops within the U5-PBS for SIV(smmPBj) replication.
    Kelly MC; Kosloff BR; Morrow CD
    Virology; 2007 Sep; 366(2):330-9. PubMed ID: 17543363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 reverse transcription initiation: a potential target for novel antivirals?
    Abbink TE; Berkhout B
    Virus Res; 2008 Jun; 134(1-2):4-18. PubMed ID: 18255184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forced selection of a human immunodeficiency virus type 1 variant that uses a non-self tRNA primer for reverse transcription: involvement of viral RNA sequences and the reverse transcriptase enzyme.
    Abbink TE; Beerens N; Berkhout B
    J Virol; 2004 Oct; 78(19):10706-14. PubMed ID: 15367637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alleviation of murine leukemia virus repression in embryonic carcinoma cells by genetically engineered primer binding sites and artificial tRNA primers.
    Modin C; Lund AH; Schmitz A; Duch M; Pedersen FS
    Virology; 2000 Dec; 278(2):368-79. PubMed ID: 11118360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of human immunodeficiency virus type 1 reverse transcriptase primer tRNA binding by fluorescence spectroscopy: specificity and comparison to primer/template binding.
    Thrall SH; Reinstein J; Wöhrl BM; Goody RS
    Biochemistry; 1996 Apr; 35(14):4609-18. PubMed ID: 8605212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 reverse transcriptase discriminates against non-self tRNA primers.
    Oude Essink BB; Das AT; Berkhout B
    J Mol Biol; 1996 Nov; 264(2):243-54. PubMed ID: 8951374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.